Drug Database
TE

testosterone enanthate (Vibex QS T / QS T / Xyosted)

✓ Approved

Antares Pharma, Inc. · AR · 类固醇

什么是 testosterone enanthate?

testosterone enanthate 是一种类固醇,由Antares Pharma, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Vibex QS T, QS T, Xyosted
公司Antares Pharma, Inc.
药物类别类固醇, 小分子
分子靶点AR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

testosterone enanthate 作用于 1 个分子靶点:

ARandrogen receptor (DHTR, AR8)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

testosterone enanthate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersHypogonadism✓ Approved

相关研究文献

PubMedCell death & disease2026-11-19

Involvement of HOXA3 and chaperone-mediated autophagy in DEHP-induced ferroptosis of mouse Leydig cells via regulating GPX4 expression.

Liu Yanyan Y, Guan Chenxi C, Xu Linlin L, Yang Jianhua J et al.

Impaired Leydig cell function leads to low testosterone levels, which is associated with male reproductive developmental defects and functional disorders. Exposure to di(2-ethylhexyl) phthalate (DEHP), an endocrine-disrupting chemical, can cause damage to Leydig cells, yet the underlying mechanism remains unclear. In this study, we found that DEHP exposure decreased serum testosterone levels and triggered ferroptosis of mouse Leydig cells by inhibiting GPX4 expression. Subsequently, mono(2-ethylhexyl) phthalate (MEHP), the primary active metabolite of DEHP, was shown to suppress the transcription of Gpx4 gene in TM3 cells by downregulation of HOXA3, which bound to the -264 to -258 region (RE3) of Gpx4 gene promoter. Concurrently, MEHP promoted HSC70 to recognize and degradate GPX4 protein via chaperone-mediated autophagy (CMA). Furthermore, both overexpression of HOXA3 and inhibition of CMA significantly abrogated MEHP-induced ferroptosis of TM3 cells through upregulating the expression of GPX4. Ultimately, tannic acid (TA), a natural polyphenol, was identified to increase the expression of GPX4 and inhibit MEHP-induced ferroptosis of TM3 cells, thereby alleviating DEHP-caused testicular damage in mice through the upregulation of HOXA3 and inhibition of CMA.

PMID 43052260
阅读全文 →
PubMedBMC infectious diseases2026-11-19

CT-detected gynecomastia in men living with HIV: prevalence, radiological patterns, and associated factors.

Akca Veysel V, Sarı Ferda Bacaksızlar FB, Togan Turhan T

To determine the prevalence of CT-detected gynecomastia in men living with HIV, characterize its radiological subtypes, and investigate potential associations with hormonal, clinical, virological, and treatment-related factors. This retrospective observational study included 170 adult men living with HIV who underwent thoracic computed tomography (CT) examinations performed on a Somatom Definition Flash multidetector CT scanner (Siemens Healthineers, Forchheim, Germany) between January 2023 and January 2025. CT examinations were reviewed for the presence of gynecomastia, laterality, and radiological subtype (nodular, dendritic, or diffuse). Demographic characteristics, duration of HIV infection, antiretroviral treatment (ART) regimens, hormonal parameters, body mass index (BMI), CD4 and CD8 counts, CD4/CD8 ratio, HIV RNA levels, and CDC stage were obtained from medical records. Multivariable logistic regression analyses were performed to identify factors associated with gynecomastia and its radiological subtypes. The mean age of the study population was 39.7 ± 11.8 years. Gynecomastia was identified in 60 patients (35.3%), with bilateral involvement in 86.7% of cases. Bilateral disease was present in 68.2% of nodular, 84.2% of dendritic, and 95.2% of diffuse gynecomastia cases. The prevalence of gynecomastia did not differ significantly among ART regimens (p = 0.743). Estradiol levels, testosterone levels, estradiol-to-testosterone ratio, BMI, CD4 count, CD8 count, CD4/CD8 ratio, and HIV RNA levels were not independently associated with gynecomastia. In multivariable analyses, use of DTG/3TC was associated with lower odds of gynecomastia (OR: 0.115, p = 0.033). For diffuse gynecomastia, longer duration of HIV infection was independently associated with increased odds (OR: 1.419, p = 0.005). No independent predictors were identified for nodular or dendritic gynecomastia. Gynecomastia is a common incidental finding on thoracic CT in men living with HIV, affecting more than one-third of patients in this cohort. Despite the relatively young age of the study population, the prevalence was comparable to that reported in large CT-based studies from the general Turkish population. HIV duration, rather than hormonal, immunological, or virological parameters, was associated with diffuse gynecomastia, suggesting that breast tissue changes may reflect cumulative long-term effects of HIV infection and its treatment. Not applicable.

PMID 43052786
阅读全文 →
PubMedBMC urology2026-11-19

Systemic immune-inflammation index, but not neutrophil-to-lymphocyte ratio, is a predictor for detecting clinically significant prostate cancer at first biopsy.

Lee Jeong Woo JW, Cho Min Chul MC

To determine whether systemic immune-inflammation index (SIII) and neutrophil-to-lymphocyte ratio (NLR) could be predictive factors for detecting clinically significant prostate cancers at first biopsy in men with a PSA level of 3.0-10.0 ng/ml or abnormal digital rectal examination (DRE) findings. Clinical records of 1,073 men with PSA of 3.0-10.0 ng/ml or abnormal DRE findings who underwent first prostate biopsy were reviewed. Before prostate biopsy, baseline evaluations were performed, including medical history, DRE, urinalysis, serum PSA, and blood tests such as CBC and testosterone. Clinically significant prostate cancer, NLR and SIII were defined as Gleason grade group of 2 or higher, absolute neutrophil counts/absolute lymphocyte counts, and absolute neutrophil counts x platelet counts/absolute lymphocyte counts, respectively. The overall detection rate of prostate cancer was 22.9% (246/1073). Among these 246 men with prostate cancer, clinically significant cancers were detected in 121 (49.2%) men. No statistically significant differences in NLR were noted for those with benign diseases, those with clinically insignificant cancer, and those with clinically significant cancer. The SIII for men with clinically significant cancers was significantly lower than that for men with benign diseases or clinically insignificant cancers. The multivariate logistic regression analysis showed that age, diabetes mellitus, serum PSA level, prostate volume, and SIII were independent predictors of clinically significant cancers. SIII, but not NLR, is a predictor for detecting clinically significant prostate cancer in patients with a PSA level of 3.0-10.0 ng/ml or abnormal DRE findings at first biopsy.

PMID 43052936
阅读全文 →
PubMedBehavioral and brain functions : BBF2026-11-18

Exercise intensity and testosterone modulate cognitive recovery and BDNF levels during morphine abstinence in castrated male rats.

Mohammadi Fatemeh F, Shahroodi Azadeh A, Rashidy-Pour Ali A, Miladi-Gorji Hossein H et al.

Chronic opioid exposure and subsequent abstinence are associated with persistent cognitive impairment and disrupted neuroplasticity, which may be further aggravated by opioid-induced hypogonadism. Brain-derived neurotrophic factor (BDNF) is a key regulator of neuronal plasticity in memory-related brain regions; however, the combined effects of exercise intensity and testosterone replacement during morphine abstinence remain poorly understood. This study investigated whether mild- and moderate-intensity treadmill exercise, alone or in combination with testosterone replacement, could ameliorate cognitive deficits and restore BDNF levels in morphine-abstinent castrated male rats. Rats underwent sham surgery or bilateral castration, followed by a 30-day recovery period, induction of morphine dependence (10 mg/kg, twice daily for 10 days), and a 28-day intervention consisting of sedentary conditions or treadmill exercise with or without testosterone treatment. Spatial learning and memory were evaluated using the Morris water maze, and avoidance memory was assessed using the shuttle box task. BDNF levels in the hippocampus, prefrontal cortex, and serum were quantified by ELISA. Morphine abstinence and castration impaired spatial learning, spatial memory, and avoidance memory and significantly reduced hippocampal and prefrontal cortex BDNF levels. Both mild- and moderate-intensity exercise improved cognitive performance and increased hippocampal and prefrontal cortex BDNF levels, with moderate-intensity exercise generally producing greater benefits. Testosterone replacement partially ameliorated the adverse effects of castration and improved selected behavioral and neurochemical outcomes, although its effects varied across experimental conditions. These findings suggest that appropriately prescribed exercise is an effective non-pharmacological strategy for promoting cognitive recovery and restoring neurotrophic signaling during morphine abstinence, while testosterone replacement may provide additional benefit under hypogonadal conditions.

PMID 43046266
阅读全文 →
PubMedEuropean journal of endocrinology2026-11-18

Hypogonadism in men with prolactinoma.

Broul Marek M, Hujová Aneta A, Radovnická Lucie L, Malucelli Alberto A et al.

Hypogonadism is one of the most consequential manifestations of prolactinoma in men, yet its course is often reduced to a single testosterone result. Prolactin excess can reversibly suppress hypothalamic-pituitary-gonadal signalling, whereas large tumours may damage gonadotroph function and other pituitary axes. These mechanisms create a dynamic phenotype that includes androgen-deficiency symptoms, impaired spermatogenesis, anaemia, adverse body composition, skeletal fragility and sexual dysfunction. Dopamine agonists are the usual first causal treatment, and transsphenoidal surgery is appropriate in selected patients; neither biochemical control nor tumour shrinkage proves gonadal or sexual recovery. Contemporary cohorts indicate that testosterone recovery occurs mainly during the first year but may continue through 24 months, and is more likely with smaller tumours, higher baseline or six-month testosterone, earlier prolactin normalisation and preserved pituitary function. Men with persistent symptomatic hypogonadism require a fertility-sensitive decision: continued observation when recovery remains plausible, consideration of testosterone replacement when fertility is not sought, or specialist gonadotrophin treatment when fertility is desired; clomiphene is an off-label option supported only by small uncontrolled studies. Sexual desire and erectile function should be measured separately because both may remain impaired despite eugonadism and require additional cardiometabolic, medication and psychosexual assessment. This Review integrates endocrine, reproductive and sexual outcomes into a time-resolved framework. The central principle is that prolactin control, endogenous gonadal recovery, fertility and sexual recovery are related but non-equivalent treatment goals.

PMID 43046285
阅读全文 →
PubMedClinica chimica acta; international journal of clinical chemistry2026-11-18

Metabolomic profiling reveals a BMI-independent metabolic signature in Polyendocrine metabolic ovarian syndrome.

Maraşlı Utku U, Aksun Seren S, Kablan Sevilay Erdogan SE, Nemutlu Emirhan E et al.

Polyendocrine metabolic ovarian syndrome (PMOS), formerly polycystic ovary syndrome (PCOS), is a common heterogeneous endocrine disorder characterized by metabolic alterations extending beyond obesity and androgen excess. This study aimed to define body mass index (BMI)-independent plasma metabolomic signature of PMOS and to evaluate associations with hyperandrogenism. Forty women with PMOS (mean age:22.9 ± 2.7 years; mean BMI:23.4 ± 4.6 kg/m2) and 40 age- and BMI-matched healthy women underwent clinical, biochemical, and hormonal assessment. Plasma metabolomic profiling was performed using gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). Data were analyzed by principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), false discovery rate (FDR)-adjusted univariate analysis, receiver operating characteristic (ROC) analysis, and pathway enrichment analysis. PCA and PLS-DA demonstrated clear separation between the PMOS and healthy control groups, with PLS-DA showing high discriminatory performance (accuracy = 0.95, R2 = 0.92, Q2 = 0.78; permutation test p = 0.002). After FDR correction, 31 metabolites differed significantly between groups. Threitol, a four‑carbon sugar alcohol was the strongest discriminatory metabolite (fold change = 5.86, FDR = 3.59 × 10-14) with an AUC of 0.995 (95% CI: 0.980-1.000), 95% sensitivity, and 100% specificity at the optimal cutoff. Cross-validated analysis using a linear support vector machine confirmed its discriminatory performance (AUC = 0.993, 95% CI: 0.976-1.000). Pathway analysis identified significant alterations in BCAA metabolism, alanine-aspartate-glutamate metabolism, and the citrate cycle. Threitol was inversely correlated with total testosterone, free androgen index, and AMH (all p < 0.001), whereas palmitoylcarnitine was positively correlated with total testosterone (r = 0.35, p = 0.001) and enoxolone was negatively correlated with both total testosterone (r = -0.34, p = 0.002) and AMH (r = -0.35, p = 0.001). Metabolomic profiling identifies a BMI-independent metabolic signature in PMOS characterized by alterations in BCAAs and energy metabolism. Targeted associations between specific metabolites and androgen levels support the utility of refined metabolic phenotyping in PMOS.

PMID 43051394
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多testosterone enanthate